From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.
暂无分享,去创建一个
[1] R. Samulski,et al. Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors , 2000, Journal of Virology.
[2] R. Kotin,et al. Virus-Mediated Transduction of Murine Retina with Adeno-Associated Virus: Effects of Viral Capsid and Genome Size , 2002, Journal of Virology.
[3] M. Atkinson,et al. Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors. , 2001, Diabetes.
[4] B. Hub,et al. Endocytosis of Adeno-Associated Virus Type 5 Leads to Accumulation of Virus Particles in the Golgi Compartment , 2002, Journal of Virology.
[5] U. Bantel‐Schaal,et al. Characterization of the DNA of a defective human parvovirus isolated from a genital site. , 1984, Virology.
[6] Prerna Sharma,et al. Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue , 1998, Journal of Virology.
[7] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[8] R. Samulski,et al. Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.
[9] V. Sandig,et al. Reactivation of the Previously Silenced Cytomegalovirus Major Immediate-Early Promoter in the Mouse Liver: Involvement of NFκB , 1998, Journal of Virology.
[10] T. Flotte,et al. Repeated Delivery of Adeno-Associated Virus Vectors to the Rabbit Airway , 1999, Journal of Virology.
[11] B. Davidson,et al. Viral-mediated gene transfer to mouse primary neural progenitor cells. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] P. Luthert,et al. Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus , 2002, Vision Research.
[13] D. Grimm. Production methods for gene transfer vectors based on adeno-associated virus serotypes. , 2002, Methods.
[14] J. Engelhardt,et al. Ubiquitination of both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors , 2002, Journal of Virology.
[15] James M. Allen,et al. Adeno-Associated Virus Type 6 (AAV6) Vectors Mediate Efficient Transduction of Airway Epithelial Cells in Mouse Lungs Compared to That of AAV2 Vectors , 2001, Journal of Virology.
[16] R. Heilbronn,et al. Discrimination between different types of human adeno-associated viruses in clinical samples by PCR. , 1998, Journal of virological methods.
[17] Lili Wang,et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. , 2002, The Journal of clinical investigation.
[18] H. Delius,et al. Human Adeno-Associated Virus Type 5 Is Only Distantly Related to Other Known Primate Helper-Dependent Parvoviruses , 1999, Journal of Virology.
[19] D. Russell,et al. Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2 , 1998, Journal of Virology.
[20] C. Halbert,et al. Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] J. Chiorini,et al. Adeno-Associated Virus Serotype 4 (AAV4) and AAV5 Both Require Sialic Acid Binding for Hemagglutination and Efficient Transduction but Differ in Sialic Acid Linkage Specificity , 2001, Journal of Virology.
[22] M. Lock,et al. Production of recombinant adeno-associated type 5 (rAAV5) vectors using recombinant herpes simplex viruses containing rep and cap. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] D. Duan,et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. , 2000, The Journal of clinical investigation.
[24] J. Qiu,et al. Characterization of the Transcription Profile of Adeno-Associated Virus Type 5 Reveals a Number of Unique Features Compared to Previously Characterized Adeno-Associated Viruses , 2002, Journal of Virology.
[25] R. Samulski,et al. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'γ)2 antibody , 1999, Nature Biotechnology.
[26] R. Linden,et al. The cryptic life style of adenoassociated virus , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.
[27] Terence R Flotte,et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. , 2002, Human gene therapy.
[28] R. Kotin,et al. Transposase-mediated construction of an integrated adeno-associated virus type 5 helper plasmid. , 2002, BioTechniques.
[29] R. Kotin,et al. Adeno-Associated Virus (AAV) Type 5 Rep Protein Cleaves a Unique Terminal Resolution Site Compared with Other AAV Serotypes , 1999, Journal of Virology.
[30] H. zur Hausen,et al. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. , 1984, Virology.
[31] D. Grimm,et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.
[32] C. Halbert,et al. Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression during the Initial Exposure , 1998, Journal of Virology.
[33] Philip R. Johnson,et al. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. , 1999, Human gene therapy.
[34] R. Samulski,et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] J. Schlehofer,et al. Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.
[36] Lili Wang,et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[37] James M. Allen,et al. Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes , 2000, Journal of Virology.
[38] B. Byrne,et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[39] H. Mizukami,et al. Adeno-associated virus 2 co-receptors? , 1999, Nature Medicine.
[40] M. Welsh,et al. Binding of Adeno-associated Virus Type 5 to 2,3-Linked Sialic Acid Is Required for Gene Transfer* , 2001, The Journal of Biological Chemistry.
[41] D. Duan,et al. Enhancement of Muscle Gene Delivery with Pseudotyped Adeno-Associated Virus Type 5 Correlates with Myoblast Differentiation , 2001, Journal of Virology.
[42] E. W. Harris,et al. Leber's Congenital Amaurosis and RPE65 , 2001, International ophthalmology clinics.
[43] Lili Wang,et al. Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer , 2001, Journal of Virology.
[44] D. Bleich,et al. Adeno-associated virus vector mediated gene transfer to pancreatic beta cells , 2000, Gene Therapy.
[45] Fred H. Gage,et al. Adeno-associated virus effectively mediates conditional gene modification in the brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[46] James M. Wilson,et al. Gene Therapy Vectors Based on Adeno-Associated Virus Type 1 , 1999, Journal of Virology.
[47] J. Chiorini,et al. Secreted and Transmembrane Mucins Inhibit Gene Transfer with AAV4 More Efficiently than AAV5* , 2002, The Journal of Biological Chemistry.
[48] J. Bennett,et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[49] R. Herzog,et al. Improved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector , 2002, Journal of Virology.
[50] D. Flaherty,et al. Bronchoalveolar Fluid Is Not a Major Hindrance to Virus-Mediated Gene Therapy in Cystic Fibrosis , 2002, Journal of Virology.
[51] D. Grimm,et al. DNA helicase‐mediated packaging of adeno‐associated virus type 2 genomes into preformed capsids , 2001, The EMBO journal.
[52] N. Young,et al. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. , 1996, Virology.
[53] Theresa A. Storm,et al. Nonrandom Transduction of Recombinant Adeno-Associated Virus Vectors in Mouse Hepatocytes In Vivo: Cell Cycling Does Not Influence Hepatocyte Transduction , 2000, Journal of Virology.
[54] Linda Yang,et al. Cloning and Characterization of Adeno-Associated Virus Type 5 , 1999, Journal of Virology.
[55] J. Chiorini,et al. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. , 2002, Human gene therapy.
[56] R. Kotin,et al. Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[57] A. Gown,et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.
[58] H. Mizukami,et al. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. , 2000, The Journal of general virology.
[59] N. Muzyczka. Use of adeno-associated virus as a general transduction vector for mammalian cells. , 1992, Current topics in microbiology and immunology.
[60] R. Samulski,et al. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[61] J. Engelhardt,et al. Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. , 1998, Human gene therapy.
[62] B. Davidson,et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors , 2000, Neuroreport.
[63] P. Boulanger,et al. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[64] Jean Bennett,et al. Gene therapy restores vision in a canine model of childhood blindness , 2001, Nature Genetics.
[65] D. Grimm,et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2 , 1999, Gene Therapy.
[66] P. Krammer,et al. Enhancement of cisplatin‐induced apoptosis by infection with adeno‐associated virus type 2 , 2002, International journal of cancer.
[67] R. Kotin,et al. Adeno-Associated Virus Type 5 (AAV5) but Not AAV2 Binds to the Apical Surfaces of Airway Epithelia and Facilitates Gene Transfer , 2000, Journal of Virology.
[68] R. Samulski,et al. Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.
[69] G. Kobinger,et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. , 2001, Human molecular genetics.
[70] M. Kay,et al. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[71] I. Martins,et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[72] James M. Wilson,et al. A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[73] W. Hauswirth,et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.
[74] D. Grimm,et al. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. , 1999, Human gene therapy.
[75] R. Kotin,et al. Immunological Aspects of Recombinant Adeno-Associated Virus Delivery to the Mammalian Brain , 2002, Journal of Virology.
[76] D. Russell,et al. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration , 1997, Journal of virology.
[77] R. Kotin,et al. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles , 1997, Journal of virology.
[78] M. Hoggan,et al. Serologic evidence for human infection with adenovirus-associated viruses. , 1968, Journal of the National Cancer Institute.
[79] B. Byrne,et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.